Special treat pharmaceutical (600671) announced on the evening of June 25th that its wholly-owned subsidiary, Huangshan Tianmu Anmian and Bu Nao Granules, has received the "Drug Re-registration Approval Notice" issued and approved by the Anhui Provincial Drug Administration. The medicine is used for insomnia, dizziness, headache, palpitation and other symptoms caused by neurasthenia or other chronic diseases.
ST目药：全资子公司收到药品再注册批准通知书
Special treat medication: wholly owned subsidiary has received the pharmaceutical re-registration approval notice.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.